Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Field Trip and Nue Life To Bring Psychedelic Therapy Home
The two companies are collaborating on Field Trip at Home™ Powered by Nue Life, a partnership that provides ketamine treatments from the comfort of a person’s home.Through this arrangement, Field Trip now offers increased accessibility and convenience for those interested in pursuing the powerful treatment outcomes of ketamine therapy outside of a clinic setting through Nue Life’s at-home and telehealth offerings.
Enveric to Split Into Two Companies; Spin-off Cannabinoid Pipeline
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments.
MindMed Announces Positive Results from Phase 2 LSD Trial
Microdose was at the PSYCH Symposium in London last week and the anticipation for these results was palpable. The industry has been waiting for a shot of good news.
“We are encouraged by the positive data showing that LSD produced rapid, strong and long-lasting reductions in anxiety and depression symptoms up to 16 weeks post treatment compared with a placebo,” said Dr. Miri Halperin Wernli, Executive President of MindMed.
COMPASS Pathways to Fund Study of Psilocybin for Autism
The double-blind, randomised, placebo-controlled study (“PSILAUT”) will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin.
Clearmind Announces Pre-IND Meeting Date with FDA
“This pre-IND meeting continues our diligent work towards initiating the clinical trial with CMND-100 by the end of 2022, which is of foremost importance to Clearmind in its aim to be a leader in developing psycho-targeted pharmaceuticals,” said Zuloff-Shani.
Clearmind’s lead product, CMND-100, is a novel psychedelic-derived drug candidate, exerting a significant reduced desire to consume alcoholic beverages.
